NEUROENDOCRINE; CARCINOMA
Clinical trials for NEUROENDOCRINE; CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE; CARCINOMA trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE; CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a black seed extract boost immunotherapy against a rare cancer?
Disease control CompletedThis pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 1…
Matched conditions: NEUROENDOCRINE; CARCINOMA
Phase: PHASE1 • Sponsor: Amr Mohamed MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Two-Drug combo aims to stall rare gut tumors
Disease control CompletedThis trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by …
Matched conditions: NEUROENDOCRINE; CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control CompletedThis study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…
Matched conditions: NEUROENDOCRINE; CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy shows promise for rare gut and lung cancers
Disease control CompletedThis phase 2 trial tested a combination of two drugs—pembrolizumab (Keytruda) and lenvatinib (Lenvima)—in 20 people with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow disease progressi…
Matched conditions: NEUROENDOCRINE; CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
PET scan study hints at new hope for tough gut cancer
Knowledge-focused CompletedThis study looked at 30 adults with a rare, fast-growing type of gut cancer called poorly differentiated neuroendocrine carcinoma. Researchers used a special PET scan (68Ga-DOTATATE) to measure how much of a protein called somatostatin receptor is present on tumors. The goal was …
Matched conditions: NEUROENDOCRINE; CARCINOMA
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC